- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.07. | Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH) | 53 | PR Newswire | - In a preclinical HCH model, TYRA-300 demonstrated increases in long bone length and binding against the HCH altered protein-
-TYRA remains on track to submit ACH Investigational New Drug Application... ► Artikel lesen | |
| 31.05. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.05. | Tyra Biosciences GAAP EPS of -$0.35 beats by $0.11 | 1 | Seeking Alpha | ||
| 09.05. | Tyra Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.05. | Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights | 74 | PR Newswire | - TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH IND submission expected in 2H24 -
- Cash, cash equivalents, and marketable securities of $382.5 million at Q1 2024 -
- Susan... ► Artikel lesen | |
| 07.05. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors | 35 | PR Newswire | CARLSBAD, Calif., May 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target... ► Artikel lesen | |
| 20.03. | HCH drug potential boosts Tyra Biosciences' stock PT at H.C. Wainwright | 3 | Investing.com | ||
| 20.03. | Tyra Biosciences Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 19.03. | Tyra Biosciences GAAP EPS of -$0.53 misses by $0.05 | 1 | Seeking Alpha | ||
| 19.03. | Tyra Biosciences files to sell 15.37M shares of common stock for holders | 1 | Seeking Alpha | ||
| 19.03. | Tyra Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.03. | Tyra Biosciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 19.03. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.03. | Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights | 107 | PR Newswire | - Advanced SURF301 Phase 1 oncology study; Initial Phase 1 results to be reported in 2H 2024 -- TYRA-300 Phase 2 ACH IND submission on track for 2H 2024 -- Initiated SURF201 Phase 1 study and dosed... ► Artikel lesen | |
| 02.02. | Tyra Biosciences spikes on $200M private financing | 4 | Seeking Alpha | ||
| 02.02. | Tyra Biosciences secures $200 million in private financing | 1 | Investing.com | ||
| 02.02. | Tyra Biosciences' TYRA-300 gains FDA rare paediatric disease status | 1 | Pharmaceutical Technology | ||
| 02.02. | Tyra Bio up on FDA's rare pediatric disease tag for dwarfism therapy | 1 | Reuters | ||
| 01.02. | Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia | 221 | PR Newswire | CARLSBAD, Calif., Feb. 1, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target... ► Artikel lesen |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,650 | +3,83 % | EQS-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024 | EQS-Ad-hoc: Epigenomics AG / Schlagwort(e): Halbjahresergebnis
Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024
22.07.2024 / 17:49 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,556 | +2,96 % | EQS-News: Defence Therapeutics Inc.: Defence Therapeutics erhält Unterstützung durch das CNRI-H-Projekt von Canadian Nuclear Laboratories zur Beschleunigung der Entwicklung seines Radioimmunokonjugat-Programms | EQS-News: Defence Therapeutics Inc.
/ Schlagwort(e): Sonstiges
DEFENCE THERAPEUTICS ERHÄLT UNTERSTÜTZUNG DURCH DAS CNRI-H-PROJEKT VON CANADIAN NUCLEAR LABORATORIES... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,316 | -7,60 % | Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards? | ||
| BEAM THERAPEUTICS | 33,140 | +3,02 % | Beam Therapeutics Stock Earns RS Rating Jump To 85 | ||
| ONCOLYTICS BIOTECH | 0,935 | 0,00 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights | Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET
SAN DIEGO, Calif. and CALGARY, Alberta, July 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,350 | +3,73 % | DelveInsight Business Research, LLP: Vascular Malformations Market to Grow Substantially by 2034, Assesses DelveInsight | Key Companies - ARTham Therapeutics, Neurelis, Protara Therapeutics, Recursion, Genentech, Vascular Therapies, Palvella Therapeutics | Vascular malformations represent one of the largest and most underserved segments. The current Atreatment options are limited. The market size of vascular malformations is expected to increase... ► Artikel lesen | |
| ASSERTIO | 1,505 | +2,38 % | Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024 | ||
| ARCTURUS THERAPEUTICS | 24,030 | +4,57 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs | ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,700 | +0,38 % | Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark | ||
| SIGA TECHNOLOGIES | 10,520 | +5,09 % | SIGA Technologies Inc.: SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,130 | 0,00 % | Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,160 | +0,61 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| VERVE THERAPEUTICS | 7,400 | -1,07 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, July 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,980 | -1,88 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis) | EURneffy positioned to be the first and only needle-free adrenaline option authorized for emergency treatment of allergic reactions (anaphylaxis) in Europe Positive CHMP opinion and recommendation... ► Artikel lesen | |
| RELAY THERAPEUTICS | 8,940 | -1,32 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608 | CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge... ► Artikel lesen |
TYRA BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,23 % bei einem Aktienkurs von 20,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TYRA BIOSCIENCES INC finden Sie auf Wallstreet Online.
